At the time of writing, Seres Therapeutics Inc [MCRB] stock is trading at $0.78, up 4.41%. An important factor to consider is whether the stock is rising or falling in short-term value. The MCRB shares have gain 12.46% over the last week, with a monthly amount drifted -6.21%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Seres Therapeutics Inc [NASDAQ: MCRB] stock has seen the most recent analyst activity on October 24, 2024, when JP Morgan downgraded its rating to a Underweight. On April 21, 2023, JP Morgan initiated with a Neutral rating and assigned a price target of $7 on the stock. Goldman downgraded its rating to a Sell and decreased its price target to $7 on July 23, 2021. Chardan Capital Markets upgraded its rating to Buy for this stock on March 05, 2021, but kept the price target unchanged to $30. In a note dated September 18, 2020, Chardan Capital Markets downgraded an Neutral rating on this stock and revised its target price from $32.50 to $27.50.
For the past year, the stock price of Seres Therapeutics Inc fluctuated between $0.54 and $1.53. Currently, Wall Street analysts expect the stock to reach $1.25 within the next 12 months. Seres Therapeutics Inc [NASDAQ: MCRB] shares were valued at $0.78 at the most recent close of the market. An investor can expect a potential return of 60.26% based on the average MCRB price forecast.
Analyzing the MCRB fundamentals
According to Seres Therapeutics Inc [NASDAQ:MCRB], the company’s sales were 0.00M for trailing twelve months, which represents an -100.00% plunge. To continue investigating profitability, this company’s Return on Assets is posted at 0.0, Equity is -0.0 and Total Capital is -1.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 6.65.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7351 points at the first support level, and at 0.6905 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8071, and for the 2nd resistance point, it is at 0.8345.
Ratios To Look Out For
It is important to note that Seres Therapeutics Inc [NASDAQ:MCRB] has a current ratio of 0.94. On the other hand, the Quick Ratio is 1.12, and the Cash Ratio is 0.75.
Transactions by insiders
Recent insider trading involved Young Teresa L., that happened on Feb 18 ’25 when 3338.0 shares were sold. Henn Matthew R. completed a deal on Feb 18 ’25 to sell 3953.0 shares. Meanwhile, CEO and President Shaff Eric D. sold 12726.0 shares on Feb 18 ’25.
